Document is current
Any future updates will be listed below
-
Authors
Nieddu, V. https://orcid.org/0000-0002-3300-074X
Melocchi, V. https://orcid.org/0000-0001-9656-3681
Battistini, C. https://orcid.org/0000-0003-3583-290X
Franciosa, G. https://orcid.org/0000-0001-5309-5558
Lupia, M. https://orcid.org/0000-0002-4712-3708
Stellato, C.
Bertalot, G. https://orcid.org/0000-0002-4862-7705
Olsen, J. V. https://orcid.org/0000-0002-4747-4938
Colombo, N.
Bianchi, F. https://orcid.org/0000-0001-7412-8638
Cavallaro, U. https://orcid.org/0000-0002-0884-6460
-
Funding
Funding for this research was provided by:
Fondazione Umberto Veronesi
Associazione Italiana per la Ricerca sul Cancro (MFAG-17568, IG-22827, IG-21320)
Ministero della Salute (CLEARLY, RF-2016-02362551)
Fondazione IEO-Monzino
- License Information
-
More Information
Article History
Received: 18 January 2023
Revised: 18 March 2023
Accepted: 20 March 2023
First Online: 28 March 2023
Materials availability
: All materials area available from the authors upon reasonable request. Affymetrix and RNAseq data were deposited in Gene Expression Omnibus database () with the accession numbers GSE216627 and GSE216487, respectively.
: The authors declare no competing interests.
: Informed consent was obtained from the patients enrolled in the study. This study was performed in accordance with the Declaration of Helsinki and was approved by the European Institute of Oncology Ethics Committee (protocol no. R789-IEO). Animal studies were performed following protocols approved by the fully authorized animal facility of the European Institute of Oncology and by the Italian Ministry of Health (as required by the Italian Law) (protocol no. 325/2016) and in accordance with EU directive 2010/63.
